Chin Richard 4

What Happened Richard Chin, a director of Cytek Biosciences (CTKB), received two restricted stock unit (RSU) awards on June 10, 2026: 33,333 RSUs and 18,261 RSUs, for a total of 51,594 RSUs. The awards are reported as derivative acquisitions at $0.00 per unit (no cash paid on grant). These are grants/awards (not purchases or sales) and do not indicate an immediate transfer of shares.

Key Details

• Transaction date: June 10, 2026; Form filed June 12, 2026 (appears timely within the usual 2-business-day Form 4 window).
• Award amounts: 33,333 RSUs and 18,261 RSUs (total 51,594 RSUs); grant price reported $0.00 per RSU.
• Vesting: Footnote F2 — 100% of the RSUs vest on the earlier of June 10, 2027 or the issuer’s 2027 annual meeting (if held in June 2027).
• Derivative classification: The filing lists these as derivative awards (RSUs) — see Footnote F1 stating each RSU converts to one share upon settlement.
• Shares owned after transaction: Not disclosed in the provided filing.
• Additional footnote: F3 references a vesting schedule for options (100% vest by the earlier of June 10, 2027 or the 2027 annual meeting); no option grant/option exercise was reported in the transactions listed.

Context RSUs are a promise to deliver shares in the future (typically at vesting) and are recorded as $0 at grant because no cash was exchanged. They differ from outright purchases or sales; they do not reflect an immediate buy or sell decision. Vesting next year means Chin will only receive actual shares (and any associated tax consequences) if the vesting condition is met. This type of insider filing is common for compensation and does not by itself indicate insider sentiment about the stock.